| External factors: | Palbociclib |
| Aging type: | Accelerate |
| Aging characteristic: |
| Category: | Chemical compounds |
| Phenotype: | Gastric cancer |
| Experiment: | SA-β-gal activity assay |
| Description: | Palbociclib-mediated antiproliferative effects were virtually identical in AGS and MKN-45 cells. SA-β-gal activity assay:the reduced proliferation in these cells was accompanied by an increase in the proportion of senescent cells, as assessed by senescence associated (SA)-β-galactosidase (SA-β- gal) staining. |
| Target gene: | CDK4/6//P53 |
| R-EF-Target gene: | Downregulation//Upregulation |
| Official symbol(s): | CDK4/6//P53 |
| Target gene experiment: | Western blot//SA-β-gal activity assay |
| Target gene description: | Western blot： Inhibition of CDK4/6 activity with suboptimal doses of Palbociclib (0.05 μM) together with the inhibition of autophagy using doses of 0.5 μM o f Spautin-1 (SP-1), resulted in a reduction in AGS cell proliferation that was greater than the inhibition induced by Palbociclib-only treatment .SA-β-gal activity assay：the proportion of giant, multinucleated senescent cells that were positive for SA-β-Gal activity was higher in cells treated with both drugs .Western blot:Through immunofluorescence and western blotting, an increase in total p53 levels in AGS cells treated with Palbociclib was evident,p53-deficient cells display a reduced ability to induce senescence following Palbociclib treatment. |
| Regulatory pathway: | -- |
| R-EF-Pathway: | -- |
| Pathway experiment: | -- |
| Pathway description: | -- |
Annotation: